Karuna Therapeutics Inc (NASDAQ:KRTX)
| 182.59 Delayed Data As of Mar 24 |  +6.37 / +3.61%Today’s Change | 92.26 Today|||52-Week Range 278.25 | -7.08% Year-to-Date |
Latest KRTX News | Press Releases
| Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval Mar 23 / Zacks.com - Paid Partner Content | Karuna's (KRTX) KarXT Meets Primary Goal in Schizophrenia Study Mar 21 / Zacks.com - Paid Partner Content |
| Why Shares of Karuna Therapeutics Were Up Wednesday Mar 22 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 176.22 |
| Today’s open | 175.28 |
| Day’s range | 174.17 - 183.33 |
| Volume | 31,984 |
| Average volume (3 months) | 355,551 |
| Market cap | $6.4B |
Data as of 3:59pm ET, 03/24/2023
Growth & Valuation
| Earnings growth (last year) | -77.03% |
| Earnings growth (this year) | -37.04% |
| Earnings growth (next 5 years) | -18.16% |
| Revenue growth (last year) | -71.22% |
| P/E ratio | NM |
| Price/Sales | 584.29 |
| Price/Book | 5.72 |
Competitors
| ---- |
| ---- |
| ---- |
| ---- |
Data as of 12/30/1899
Financials
| Next reporting date | May 4, 2023 |
| EPS forecast (this quarter) | -$2.75 |
| Annual revenue (last year) | $10.6M |
| Annual profit (last year) | -$276.3M |
| Net profit margin | -2,597.88% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Boston, Massachusetts |
Forecasts
